|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2008-8-20
|
|
pubmed:abstractText |
The objective was the evaluation of the effect of the Dutch national routine antenatal RhIG (anti-D) immunization prevention (RAADP) program comprising one single dose of 200 microg (1000 IU) of RhIG in the 30th week of pregnancy, restricted to women without a living child.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0041-1132
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1721-9
|
|
pubmed:meshHeading |
pubmed-meshheading:18507749-Erythroblastosis, Fetal,
pubmed-meshheading:18507749-Female,
pubmed-meshheading:18507749-Humans,
pubmed-meshheading:18507749-Infant, Newborn,
pubmed-meshheading:18507749-Isoantibodies,
pubmed-meshheading:18507749-Netherlands,
pubmed-meshheading:18507749-Parity,
pubmed-meshheading:18507749-Pregnancy,
pubmed-meshheading:18507749-Pregnancy Trimester, First,
pubmed-meshheading:18507749-Retrospective Studies,
pubmed-meshheading:18507749-Rh Isoimmunization,
pubmed-meshheading:18507749-Rho(D) Immune Globulin,
pubmed-meshheading:18507749-Risk Factors,
pubmed-meshheading:18507749-Risk Reduction Behavior,
pubmed-meshheading:18507749-Seroepidemiologic Studies,
pubmed-meshheading:18507749-Severity of Illness Index
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy.
|
|
pubmed:affiliation |
Sanquin Research, Amsterdam, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
